New trial shows top-selling Lundbeck drug not beating placebo for borderline

A phase II trial of one of Lundbeck's best-selling drugs for borderline personality disorder has not shown the hoped-for result, as the drug doesn't outperform the placebo treatment in the study's focal point.

Photo: Lundbeck / PR

Lundbeck suffers a setback in its attempts to promote the use of Rexulti, which is already among the company's best-selling products, reads the pharmaceutical company's Q2 report released Wednesday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs